a clustered regularly interspaced short palindromic repeat (CRISPR)-associated (Cas) protein having an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 77% identity therewith;

at least one targeting RNA molecule which recognizes the target nucleic acid sequence in the target nucleic acid strand, wherein the non-target strand further comprises a protospacer adjacent motif (PAM) sequence directly adjacent the 3' end of the protospacer sequence, wherein the PAM sequence comprises 5'-NNNNCNN-3'; and

an expression vector comprising a nucleic acid encoding at least one of said Cas protein and said targeting RNA molecule; optionally wherein the human cell is not an embryonic stem cell.

In another aspect, the present disclosure refers to an *in vitro* method of binding, cleaving, marking or modifying a double stranded target polynucleotide in a human cell, wherein the double stranded target polynucleotide comprises a target nucleic acid strand comprising a target nucleic acid sequence, and a non-target nucleic acid strand comprising a protospacer nucleic acid sequence complementary to the target nucleic acid sequence, said method comprising:

a. designing at least one targeting RNA molecule, wherein the targeting RNA molecule recognizes the target sequence in the target strand, and the non-target strand further comprises a protospacer adjacent motif (PAM) sequence directly adjacent the 3' end of the protospacer sequence, wherein the PAM sequence comprises 5'-NNNNCNN-3';

b. forming a ribonucleoprotein complex comprising the targeting RNA molecule and a Cas protein, wherein the isolated Cas protein has an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 77% identity therewith; and

c. the ribonucleoprotein complex binding, cleaving, marking or modifying the target polynucleotide; optionally wherein said human cell is not an embryonic stem cell; and optionally wherein the method does not modify the germ line genetic identity of a human being.

In yet another aspect, the present disclosure refers to the *in vitro* use of at least one targeting RNA molecule and a Cas protein to form a nucleoprotein complex for binding, cleaving, marking or modifying a double stranded target polynucleotide comprising a target nucleic acid sequence, wherein:

the double stranded target polynucleotide comprises a target nucleic acid strand, comprising said target nucleic acid sequence, and a non-target nucleic acid strand, comprising a protospacer nucleic acid sequence complementary to the target nucleic acid sequence;

the Cas protein has an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 77% identity therewith;

the at least one targeting RNA molecule recognizes the target sequence;

the non-target nucleic acid strand further comprises a protospacer adjacent motif (PAM) sequence directly adjacent to the 3' end of the protospacer nucleic acid sequence, wherein the PAM sequence comprises 5'-NNNNCNN-3'; wherein said use is in a human cell; and optionally wherein said human cell is not an embryonic stem cell.

Accordingly, the present disclosure provides an isolated clustered regularly interspaced short palindromic repeat (CRISPR)-associated (Cas) protein or polypeptide comprising;

a. the amino acid motif EKDGKYYC [SEQ ID NO: 2]; and/or
b. the amino acid motif $X_1X_2CTX_3X_4$ [SEQ ID NO: 3] wherein X_1 is independently selected from Isoleucine, Methionine or Proline, X_2 is independently selected from Valine, Serine, Asparagine or Isoleucine, X_3 is independently selected from Glutamate or Lysine and X_4 is one of Alanine, Glutamate or Arginine; and/or
c. the amino acid motif X_5LKX_6IE [SEQ ID NO: 4] wherein X_5 is independently selected from Methionine or Phenylalanine and X_6 is independently selected from Histidine or Asparagine; and/or
d. the amino acid motif X_7VYSX_8K [SEQ ID NO: 5] wherein X_7 is Glutamate or Isoleucine and X_8 is one of Tryptophan, Serine or Lysine; and/or

CLAIMS

1. A nucleoprotein complex comprising a Cas protein, at least one targeting RNA molecule which recognises a target nucleic acid sequence in a double stranded target polynucleotide, and the target polynucleotide, wherein

the Cas protein has an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 77% identity therewith;

the double stranded target polynucleotide comprises a target nucleic acid strand, comprising said target nucleic acid sequence, and a non-target nucleic acid strand, comprising a protospacer nucleic acid sequence complementary to the target nucleic acid sequence and a protospacer adjacent motif (PAM) sequence directly adjacent the 3' end of the protospacer sequence, wherein the PAM sequence comprises 5'-NNNNCNN-3'; wherein the nucleoprotein complex is in a human cell; and optionally wherein said cell is not an embryonic stem cell.

2. A transformed human cell, having a double stranded target polynucleotide comprising a target nucleic acid sequence, wherein the double stranded target polynucleotide comprises a target nucleic acid strand, comprising said target nucleic acid sequence, and a non-target nucleic acid strand, comprising a protospacer nucleic acid sequence complementary to the target nucleic acid sequence, said cell comprising:

a clustered regularly interspaced short palindromic repeat (CRISPR)-associated (Cas) protein having an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 77% identity therewith;

at least one targeting RNA molecule which recognizes the target nucleic acid sequence in the target nucleic acid strand, wherein the non-target strand further comprises a protospacer adjacent motif (PAM) sequence directly adjacent the 3' end of the protospacer sequence, wherein the PAM sequence comprises 5'-NNNNCNN-3'; and

an expression vector comprising a nucleic acid encoding at least one of said Cas protein and said targeting RNA molecule; optionally wherein the human cell is not an embryonic stem cell.

3. A transformed cell as claimed in claim 2, wherein the Cas protein is expressed from an expression vector.

4. A nucleoprotein complex as claimed in claim 1, or a transformed cell as claimed in claim 2 or claim 3, wherein the Cas protein has an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 89% identity therewith.

5. A nucleoprotein complex as claimed in claim 1 or claim 4, or a transformed cell as claimed in any of claims 2 to 4, wherein the nucleoprotein complex occurs at a temperature between 20°C and 100°C, at a temperature between 30°C and 80°C, or at a temperature between 37°C and 78°C, preferably at a temperature above 55°C; more preferably at a temperature between 55°C and 80°C; even more preferably at a temperature between 55°C and 65°C or 60°C and 65°C.

6. A nucleoprotein complex or a transformed cell as claimed in any preceding claim, wherein the double stranded target polynucleotide comprising the target nucleic acid sequence is cleaved by the Cas protein; preferably wherein said cleavage is DNA cleavage.

7. A transformed cell as claimed in any of claims 3 to 5, wherein (i) the binding, cleaving, marking or modifying is at a temperature between 20°C and 100°C, at a temperature between 30°C and 80°C, or at a temperature between 37°C and 78°C; preferably at a temperature above 55°C; more preferably at a temperature between 55°C and 80°C; even more preferably at a temperature between 55°C and 65°C or 60°C and 65°C; and/or (ii) the target polynucleotide comprising the target sequence is double stranded DNA and saidcleaving results in a double stranded break in the target polynucleotide.

8. A transformed cell or a nucleoprotein complex as claimed in any of claims 1 to 5, wherein the Cas protein lacks nuclease activity to cut the double stranded DNA yet there is gene silencing of the target polynucleotide.

9. A transformed cell or a nucleoprotein complex as claimed in any preceding claim, wherein the PAM sequence comprises 5'-NNNNCNNA-3' [SEQ ID NO: 47]; preferably wherein the PAM sequence comprises 5'-NNNNCSAA-3' [SEQ ID NO: 48]; more preferably wherein the PAM sequence comprises 5'-NNNNCCAA-3' [SEQ ID NO: 50].

10. A nucleoprotein complex as claimed in claim 1 or claim 4, or a transformed cell as claimed in any of claims 2 to 4, wherein the nucleoprotein complex forms at a temperature between 20°C and 70°C; preferably at a temperature between 25°C and 65°C.

11. A transformed cell as claimed in any of claims 3 to 5, wherein the binding, cleaving, marking or modifying occurs at a temperature between 20°C and 70°C; preferably at a temperature between 25°C and 65°C.12. A transformed cell or a nucleoprotein complex as claimed in any preceding claim, wherein the targeting RNA molecule comprises a crRNA and a tracrRNA.

13. A transformed cell or a nucleoprotein complex as claimed in any preceding claim, wherein the length of the at least one targeting RNA molecule is in the range 35 – 200 nucleotide residues; and/or wherein the target nucleic acid sequence is from 15 to 32 nucleotide residues in length.

14. A transformed cell or a nucleoprotein complex as claimed in any preceding claim, wherein the nuclease activity of the Cas protein is optionally inactive and the Cas protein further comprises at least one functional moiety; preferably a protein; optionally selected from a helicase, a nuclease, a helicase-nuclease, a DNA methylase, a histone methylase, an acetylase, a phosphatase, a kinase, a transcription (co-)activator, a transcription repressor, a DNA binding protein, a DNA structuring protein, a marker protein, a reporter protein, a fluorescent protein, a ligand binding protein, a signal peptide, a subcellular localisation sequence, an antibody epitope or an affinity purification tag, for example a green fluorescent protein (GFP).

15. An *in vitro* method of binding, cleaving, marking or modifying a double stranded target polynucleotide in a human cell, wherein the double stranded target polynucleotide comprises a target nucleic acid strand comprising a target nucleic acid sequence, and a non-target nucleic acid strand comprising a protospacer nucleic acid sequence complementary to the target nucleic acid sequence, said method comprising:

a. designing at least one targeting RNA molecule, wherein the targeting RNA molecule recognizes the target sequence in the target strand, and the non-target

strand further comprises a protospacer adjacent motif (PAM) sequence directly adjacent the 3' end of the protospacer sequence, wherein the PAM sequence comprises 5'-NNNNCNN-3';

b. forming a ribonucleoprotein complex comprising the targeting RNA molecule and a Cas protein, wherein the isolated Cas protein has an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 77% identity therewith; and

c. the ribonucleoprotein complex binding, cleaving, marking or modifying the target polynucleotide; optionally wherein said human cell is not an embryonic stem cell; and optionally wherein the method does not modify the germ line genetic identity of a human being.

16. *In vitro* use of at least one targeting RNA molecule and a Cas protein to form a nucleoprotein complex for binding, cleaving, marking or modifying a double stranded target polynucleotide comprising a target nucleic acid sequence, wherein:

the double stranded target polynucleotide comprises a target nucleic acid strand, comprising said target nucleic acid sequence, and a non-target nucleic acid strand, comprising a protospacer nucleic acid sequence complementary to the target nucleic acid sequence;

the Cas protein has an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 77% identity therewith;

the at least one targeting RNA molecule recognizes the target sequence;

the non-target nucleic acid strand further comprises a protospacer adjacent motif (PAM) sequence directly adjacent to the 3' end of the protospacer nucleic acid sequence, wherein the PAM sequence comprises 5'-NNNNCNN-3'; wherein said use is in a human cell; and optionally wherein said human cell is not an embryonic stem cell.

17. An *in vitro* method as claimed in claim 15 or an *in vitro* use as claimed in claim 16, wherein the Cas protein has an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 89% identity therewith. 18.An *in vitro* method as claimed in claim 15 or claim 17, or an *in vitro* use as claimed in claim 16 or claim 17, wherein the nucleoprotein complex forms at a temperature between 20°C and 100°C, at a

temperature between 30°C and 80°C, or at a temperature between 37°C and 78°C, preferably at a temperature above 55°C; more preferably at a temperature between 55°C and 80°C; even more preferably at a temperature between 55°C and 65°C or 60°C and 65°C.

19. An *in vitro* method as claimed in any of claims 15, 17 or 18, or an *in vitro* use as claimed in any of claims 16 to 18, wherein the PAM sequence comprises 5'-NNNNCNNA-3', 5'-CNNNCNN-3', 5'-NNNCCNN-3', 5'-NNCNCNN-3', 5'-NNNNCCN-3', and/or 5'-NCNNCNN-3'; preferably wherein the PAM sequence comprises 5'-CCCCCCNA-3' [SEQ ID NO: 10], more preferably wherein the PAM sequence comprises 5'-CCCCCCAA-3' [SEQ ID NO: 11].

20. An *in vitro* method as claimed in any of claims 15, 17, 18 or 19, or an *in vitro* use as claimed in any of claims 16 to 19, wherein the Cas protein further comprises at least one functional moiety; preferably a protein; optionally selected from a helicase, a nuclease, a helicase-nuclease, a DNA methylase, a histone methylase, an acetylase, a phosphatase, a kinase, a transcription (co-)activator, a transcription repressor, a DNA binding protein, a DNA structuring protein, a marker protein, a reporter protein, a fluorescent protein, a ligand binding protein, a signal peptide, a subcellular localisation sequence, an antibody epitope or an affinity purification tag, for example a green fluorescent protein (GFP).